[go: up one dir, main page]

FI931458A0 - PYRIMIDINDERIVAT OCH FOERFARANDE FOER DERAS FRAMSTAELLNING - Google Patents

PYRIMIDINDERIVAT OCH FOERFARANDE FOER DERAS FRAMSTAELLNING

Info

Publication number
FI931458A0
FI931458A0 FI931458A FI931458A FI931458A0 FI 931458 A0 FI931458 A0 FI 931458A0 FI 931458 A FI931458 A FI 931458A FI 931458 A FI931458 A FI 931458A FI 931458 A0 FI931458 A0 FI 931458A0
Authority
FI
Finland
Prior art keywords
stands
free
substituted
amino
lower alkyl
Prior art date
Application number
FI931458A
Other languages
Finnish (fi)
Other versions
FI109534B (en
FI931458A7 (en
Inventor
Juerg Zimmermann
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4202064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI931458(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI931458A0 publication Critical patent/FI931458A0/en
Publication of FI931458A7 publication Critical patent/FI931458A7/en
Application granted granted Critical
Publication of FI109534B publication Critical patent/FI109534B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Paints Or Removers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

There are described N-phenyl-2-pyrimidinamine derivatives of the formula I <IMAGE> in which R1 denotes 4-pyrazinyl, 1-methyl-1H-pyrrolyl, phenyl substituted by amino or amino-lower alkyl, in which the amino group is in each case free, alkylated or acylated, 1H-indolyl or 1H-imidazolyl bonded to a five-membered ring carbon atom, or pyridyl which is bonded to a ring carbon atom, unsubstituted or substituted by lower alkyl and unsubstituted or substituted by oxygen on the nitrogen, R2 and R3 independently of one another each denote hydrogen or lower alkyl, one or two of the radicals R4, R5, R6, R7 and R8 each denote nitro, fluorine-substituted lower alkoxy or a radical of the formula II -N(R9)-C(=X)-Y)n-R10 (II> in which R9 stands for hydrogen or lower alkyl, X stands for oxo, thio, imino, N-lower alkylimino, hydroximino or O-lower alkylhydroxyimino, Y stands for oxygen or the group NH, n stands for 0 or 1 and R10 stands for an aliphatic radical having at least 5 C atoms or for an aromatic, aromatic-aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, heterocyclic or heterocyclic-aliphatic radical, and the remainder of the radicals R4, R5, R6, R7 and R8 independently of one another each denote hydrogen, lower alkyl which is unsubstituted or substituted by free or alkylated amino, piperazinyl, piperidinyl, pyrrolidinyl or morpholinyl, lower alkanoyl, trifluoromethyl, free, etherified or esterified hydroxyl, free, alkylated or acylated amino or free or esterified carboxyl. These compounds can be used e.g. for the therapy of cancers.
FI931458A 1992-04-03 1993-03-31 Process for the preparation of pharmacologically active pyrimidine derivatives FI109534B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH108392 1992-04-03
CH108392 1992-04-03

Publications (3)

Publication Number Publication Date
FI931458A0 true FI931458A0 (en) 1993-03-31
FI931458A7 FI931458A7 (en) 1993-10-04
FI109534B FI109534B (en) 2002-08-30

Family

ID=4202064

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931458A FI109534B (en) 1992-04-03 1993-03-31 Process for the preparation of pharmacologically active pyrimidine derivatives

Country Status (29)

Country Link
EP (1) EP0564409B1 (en)
JP (1) JP2706682B2 (en)
KR (1) KR100261366B1 (en)
CN (1) CN1043531C (en)
AT (1) ATE188964T1 (en)
AU (1) AU666709B2 (en)
BR (1) BR1100739A (en)
CA (1) CA2093203C (en)
CY (2) CY2229B1 (en)
CZ (1) CZ283944B6 (en)
DE (2) DE10299016I2 (en)
DK (1) DK0564409T3 (en)
ES (1) ES2142857T3 (en)
FI (1) FI109534B (en)
GR (1) GR3032927T3 (en)
HU (2) HU227080B1 (en)
IL (1) IL105264A (en)
LU (1) LU90908I2 (en)
MX (1) MX9301929A (en)
NL (1) NL300086I2 (en)
NO (2) NO302473B1 (en)
NZ (1) NZ247299A (en)
PT (1) PT564409E (en)
RU (1) RU2125992C1 (en)
SA (1) SA93140441B1 (en)
SG (1) SG43859A1 (en)
SK (1) SK280620B6 (en)
TW (1) TW225528B (en)
ZA (1) ZA932397B (en)

Families Citing this family (351)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
US6171786B1 (en) 1992-09-17 2001-01-09 Board Of Trustees Of University Of Illinois Methods for preventing multidrug resistance in cancer cells
US5972598A (en) * 1992-09-17 1999-10-26 Board Of Trustess Of The University Of Illinois Methods for preventing multidrug resistance in cancer cells
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
WO1995009853A1 (en) * 1993-10-01 1995-04-13 Ciba-Geigy Ag Pharmacologically active pyridine derivatives and processes for the preparation thereof
ES2262137T3 (en) * 1993-10-01 2006-11-16 Novartis Ag PHARMACOLOGICALLY ACTIVE PIRIMIDINAMINE DERIVATIVES AND PROCEDURES FOR THEIR PREPARATION.
JPH08503971A (en) * 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト Pyrimidineamine derivatives and methods for their preparation
GB9325217D0 (en) * 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
JP3806144B2 (en) * 1993-12-22 2006-08-09 セルテック セラピューティックス リミテッド Trisubstituted phenyl derivatives, their preparation and their use as phosphodiesterase (type IV) inhibitors
GB9326699D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5756527A (en) * 1995-06-07 1998-05-26 Ontogen Corporation Imidazole derivatives useful as modulators of multi drug resistances
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
EP0812829A1 (en) * 1996-06-14 1997-12-17 Ontogen Corporation Substituted imidazoles as modulators of multi-drug resistance
EP0812830A1 (en) * 1996-06-14 1997-12-17 Ontogen Corporation Modulators of multi-drug resistances
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
JP2001507349A (en) * 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
CO4940418A1 (en) * 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6498165B1 (en) 1999-06-30 2002-12-24 Merck & Co., Inc. Src kinase inhibitor compounds
CA2376957A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
AU5889100A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
BR0013899A (en) 1999-09-10 2003-07-08 Merck & Co Inc A compound, pharmaceutical composition, processes for treating or preventing cancer, a disease in which angiogenesis is implicated, retinal vascularization, diabetic retinopathy, age-related macular degeneration, inflammatory diseases, tyrosine-dependent disease or conditions. kinase, bone-associated pathologies, and processes for producing a pharmaceutical composition, and for reducing or preventing tissue damage following a cerebral ischemic event
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
AU2001237041B9 (en) * 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
JP5073147B2 (en) 2000-08-18 2012-11-14 ミレニアム ファーマシューティカルズ インク. Quinazoline derivatives as kinase inhibitors
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
HU229106B1 (en) * 2000-10-27 2013-07-29 Novartis Ag Treatment of gastrointestinal stromal tumors
EP1330444B1 (en) 2000-11-01 2011-03-23 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds and process for making them
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
EP3143995B2 (en) 2001-02-19 2025-01-15 Novartis Pharma AG Rapamycin derivative for the treatment of lung cancer
SE0100569D0 (en) * 2001-02-20 2001-02-20 Astrazeneca Ab New compounds
MXPA03007729A (en) 2001-02-27 2003-12-04 Novartis Ag Combination comprising a signal transduction inhibitor and an epothilone derivative.
CN1700917B (en) 2001-05-16 2010-04-28 诺瓦提斯公司 Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
EP1395261B1 (en) * 2001-05-16 2006-06-28 GPC Biotech AG Pyridylpyrimidine derivatives as effective compounds against prion diseases
US7521175B2 (en) 2001-06-14 2009-04-21 The Regents Of The University Of California Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
AU2002315388A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel phenylamino-pyrimidines and uses thereof
AU2002346053B2 (en) 2001-06-22 2008-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2452368A1 (en) 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
EP1401416B1 (en) 2001-06-29 2006-10-25 AB Science Use of c-kit inhibitors for treating inflammatory bowel diseases (ibd)
ATE345839T1 (en) 2001-06-29 2006-12-15 Ab Science THE USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF ALLERGY DISEASES
DE60212627T2 (en) 2001-06-29 2007-06-14 Ab Science Use of tyrosine kinase inhibitors for the treatment of inflammatory diseases
JP2004530730A (en) * 2001-06-29 2004-10-07 アブ サイエンス Use of a potent, selective and non-toxic c-kit inhibitor for treating tumor angiogenesis
JP2005511596A (en) * 2001-09-20 2005-04-28 アブ サイエンス Methods of using tyrosine kinase inhibitors for whitening human skin and treating diseases associated with melanocyte dysfunction
WO2003040141A1 (en) * 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
EP2343365A1 (en) 2001-10-05 2011-07-13 Novartis AG Mutated Abl kinase domains
GB0201508D0 (en) 2002-01-23 2002-03-13 Novartis Ag Organic compounds
GB0202874D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
AU2007203462B2 (en) * 2002-02-07 2011-01-06 Novartis Pharma Ag N-phenyl-2-pyrimidine-amine derivatives
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
DE60305460D1 (en) * 2002-02-22 2006-06-29 Us Government USE OF 4- (4-METHYLPIPERAZINE-1-YLMETHYL) -N 4-METHYL-3- (4-PYRIDIN-3-YL) PYRIMIDIN-2-YLAMINO) PHENYL BENZAMIDE FOR THE TREATMENT OF SEMINOMES
CA2477111A1 (en) * 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating cns disorders
ES2314223T3 (en) * 2002-02-27 2009-03-16 Ab Science USE OF THYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DISORDERS FOR USE OF SUBSTANCES.
CN1326577C (en) * 2002-02-28 2007-07-18 诺瓦提斯公司 N-{5-[4-(4-methyl-piperazino-methyl)--benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
WO2003095448A1 (en) * 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
AU2003240655B2 (en) 2002-05-16 2007-09-06 Novartis Ag Use of EDG receptor binding agents in cancer
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
US20060052387A1 (en) * 2002-06-26 2006-03-09 Marsh Clay B Organic compounds
ES2337995T3 (en) * 2002-06-28 2010-05-03 Nippon Shinyaku Co., Ltd. DERIVATIVE OF AMIDA.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
MXPA05001277A (en) * 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors.
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
AU2003273986A1 (en) * 2002-10-11 2004-05-04 Novartis Ag Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents
GB0224455D0 (en) * 2002-10-21 2002-11-27 Novartis Ag Organic compounds
US7094785B1 (en) 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
WO2004087234A1 (en) * 2003-04-04 2004-10-14 Bayco Tech Limited Vascular stent
AU2003232650A1 (en) * 2003-05-06 2004-11-26 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
EP1628967B1 (en) 2003-05-19 2014-04-09 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
MXPA05012739A (en) * 2003-05-27 2006-05-17 Robert Per Hagerkvist Use of tyrosine kinase inhibitor to treat diabetes.
WO2004110452A1 (en) * 2003-06-13 2004-12-23 Novartis Ag 2-aminopyrimidine derivatives as raf kinase inhibitors
CN102380098B (en) 2003-08-27 2015-07-22 奥普索特克公司 Combination therapy for the treatment of ocular neovascular disorders
BRPI0416680A (en) 2003-11-18 2007-02-13 Novartis Ag mutant form inhibitors
LT1702917T (en) * 2003-12-25 2017-12-11 Nippon Shinyaku Co., Ltd. Amide derivative and medicine
EP1725295B1 (en) 2004-01-21 2010-09-15 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
PE20051096A1 (en) 2004-02-04 2006-01-23 Novartis Ag SALT FORMS OF 4- (4-METHYLPIPERAZIN-1-ILMETHYL) -N- [4-METHYL-3- (4-PYRIDIN-3-IL) PYRIMIDIN-2-ILAMINO) PHENYL] -BENZAMIDE
EP1720853B2 (en) 2004-02-11 2023-06-28 Natco Pharma Limited Pharmaceutical compositions of the 2 crystalline form of imatinib mesylate for use in the treatment of chronic myelogenous leukemia
CN1309719C (en) * 2004-02-18 2007-04-11 陈国庆 Derivative of phenylamide pyrimidine and application thereof
EP1735307B1 (en) 2004-04-07 2012-08-29 Novartis AG Inhibitors of iap
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US20080187575A1 (en) * 2004-08-27 2008-08-07 Bert Klebl Pyrimidine Derivatives
WO2006024863A1 (en) 2004-09-02 2006-03-09 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US7939541B2 (en) * 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
KR100948453B1 (en) 2004-09-09 2010-03-17 낫코 파마 리미티드 Novel Phenylaminopyrimidine Derivatives as WRC-ALLL Kinase Inhibitors
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
DE602005023658D1 (en) * 2004-12-30 2010-10-28 Inst Farmaceutyczny PROCESS FOR THE PRODUCTION OF IMATINIB BASE
CN1972917B (en) * 2004-12-31 2010-08-25 孙飘扬 Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
CN1939910A (en) * 2004-12-31 2007-04-04 孙飘扬 Amino-metadiazine compound and its salt, its preparation and pharmaceutical use
WO2006077424A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
CA2606716C (en) 2005-05-02 2013-07-23 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of systematic mastocytosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
UA96139C2 (en) 2005-11-08 2011-10-10 Дженентек, Інк. Anti-neuropilin-1 (nrp1) antibody
EP2275103B1 (en) 2005-11-21 2014-04-23 Novartis AG mTOR inhibitors in the treatment of endocrine tumors
CN102351842B (en) 2005-11-25 2014-07-23 诺华股份有限公司 F,G,H,I and K crystal forms of imatinib mesylate
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
RU2452492C2 (en) 2006-04-05 2012-06-10 Новартис Аг COMBINATIONS CONTAININS Bcr-Abl/c-Kit/PDGF-RTK INHIBITORS FOR TREATING CANCER
KR20080108517A (en) 2006-04-05 2008-12-15 노파르티스 아게 Combination of Therapeutics to Treat Cancer
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
CN101443002B (en) 2006-05-09 2012-03-21 诺瓦提斯公司 Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
US20060223817A1 (en) * 2006-05-15 2006-10-05 Chemagis Ltd. Crystalline imatinib base and production process therefor
WO2007138705A1 (en) 2006-06-01 2007-12-06 Japan As Represented By Director General Of Agency Of National Cancer Center Tumor suppressor
BRPI0717564A2 (en) 2006-09-29 2013-10-22 Novartis Ag PIRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5528807B2 (en) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド Compound drug
JP2009514988A (en) * 2006-10-26 2009-04-09 シコール インコーポレイティド Imatinib base and imatinib mesylate and methods for their preparation
WO2008059551A2 (en) 2006-11-16 2008-05-22 F.I.S. Fabbrica Italiana Sintetici S.P.A. Process for the preparation of imatinib and intermediates thereof
CN101245061B (en) * 2007-02-13 2012-09-19 天津天士力集团有限公司 N-(5-amido-2-methyl phenyl)-4-(3-pyridinyl)-2-aminopyrimidine nitric oxide donating derivant, production method and uses thereof
EP2120900A2 (en) 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer
RU2329260C1 (en) * 2007-02-20 2008-07-20 Юрий Иосифович Копырин Method of obtaining 2-anilinopyrimidines or their salts (options)
MX2009009659A (en) * 2007-03-12 2009-09-22 Reddys Lab Ltd Dr Imatinib mesylate.
WO2008117298A1 (en) * 2007-03-26 2008-10-02 Natco Pharma Limited A novel method of preparation of imatinib
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008136010A1 (en) * 2007-05-07 2008-11-13 Natco Pharma Limited A process for the preparation of highly pure imatinib base
US8367686B2 (en) 2007-06-07 2013-02-05 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
EP2166860B1 (en) 2007-06-07 2016-09-21 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
JP5611826B2 (en) * 2007-09-04 2014-10-22 ザ スクリプス リサーチ インスティテュート Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009060463A1 (en) * 2007-11-05 2009-05-14 Natco Pharma Limited An environmentally friendly process for the preparation of imatinib base
EP2062885A1 (en) * 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
RU2493152C2 (en) * 2008-02-01 2013-09-20 Акинион Фармасьютикалз Аб Novel compounds, use and production thereof
BRPI0908603A2 (en) 2008-03-24 2020-08-18 Novartis Ag matrix metalloprotease inhibitors based on arylsulfonamide.
JP5330498B2 (en) 2008-03-26 2013-10-30 ノバルティス アーゲー Hydroxamate-based inhibitors of deacetylase B
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CN101584696A (en) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 Composition containing quinazoline derivatives, preparation method and use
KR101860057B1 (en) 2008-05-21 2018-05-21 어리어드 파마슈티칼스, 인코포레이티드 Phosphorous derivatives as kinase inhibitors
PL215042B1 (en) * 2008-08-01 2013-10-31 Temapharm Spolka Z Ograniczona Odpowiedzialnoscia Method of imatinib manufacturing
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
AU2009281122C1 (en) 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
EA023148B1 (en) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Compositions of pd-1 antagonists and use thereof
ES2704986T3 (en) 2008-10-16 2019-03-21 Celator Pharmaceuticals Inc Combinations of a water-soluble liposomal camptothecin with cetuximab or bevacizumab
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
CN103204794A (en) 2008-12-18 2013-07-17 诺瓦提斯公司 New Salts
UY32330A (en) 2008-12-18 2010-07-30 Novartis Ag NEW FORM OF SALT OF ACID 1- (4- {1- [E-4-CICLOHEXIL-3-TRIFLUORO-METIL-BENCILOXI-IMINO] -ETIL} -2-ETIL-BENCIL) -AZETIDIN-3-CARBOXYLICAL, POLYMODIC FORMS , PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
WO2010071794A1 (en) 2008-12-18 2010-06-24 Novartis Ag New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
BRPI0923121A2 (en) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Saline forms of organic compounds
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
TWI466672B (en) 2009-01-29 2015-01-01 Boehringer Ingelheim Int Treatment for diabetes in paediatric patients
JP2012516345A (en) 2009-01-29 2012-07-19 ノバルティス アーゲー Substituted benzimidazoles for astrocytoma treatment
EA029759B1 (en) 2009-02-13 2018-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Antidiabetic medications comprising dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetic agents
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519282A (en) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー Methods for identifying mesenchymal tumor cells or agents that inhibit their production
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (en) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー Methods for identifying mesenchymal tumor cells or agents that inhibit their production
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
EA021011B1 (en) 2009-06-26 2015-03-31 Новартис Аг 1,3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF Cyp 17
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (en) 2009-08-12 2012-02-29 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
SG10201404886PA (en) 2009-08-17 2014-10-30 Intellikine Llc Heterocyclic compounds and uses thereof
EP2467383A1 (en) 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
WO2011023677A1 (en) 2009-08-26 2011-03-03 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
EA201200471A1 (en) 2009-09-10 2012-10-30 Новартис Аг SIMPLE ESSENTIAL DERIVATIVES OF BICYCLIC HETEROARILS
NZ598170A (en) 2009-10-02 2014-06-27 Boehringer Ingelheim Int Pharmaceutical compositions comprising bi-1356 and metformin
CN102686579A (en) 2009-10-09 2012-09-19 Irm责任有限公司 Compounds and compositions as modulators of GPR119 activity
PL389357A1 (en) 2009-10-22 2011-04-26 Tomasz Koźluk Tartaric acids derivatives imatinib salts and process for the preparation thereof
EP2496575B1 (en) 2009-11-04 2014-04-30 Novartis AG Heterocyclic sulfonamide derivatives useful as mek inhibitors
EA201200617A1 (en) 2009-11-23 2012-11-30 Серулин Фарма Инк. POLYMERS ON THE BASIS OF CYCLODEXTRINE FOR DELIVERY OF MEDICINES
WO2011064211A1 (en) 2009-11-25 2011-06-03 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
JP2013512229A (en) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Treatment of diabetic patients whose genotype has been identified with DDP-IV inhibitors such as linagliptin
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
JP5456908B2 (en) 2009-12-08 2014-04-02 ノバルティス アーゲー Heterocyclic sulfonamide derivatives
WO2012168884A1 (en) 2011-06-09 2012-12-13 Novartis Ag Heterocyclic sulfonamide derivatives
EP2509973A1 (en) 2009-12-10 2012-10-17 Arch Pharmalabs Limited Process for the preparation of imatinib and salts thereof
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (en) 2009-12-22 2015-09-29 Novartis Ag ISOQUINOLINONES AND REPLACED QUINAZOLINONES
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2011099039A1 (en) 2010-02-15 2011-08-18 Reliance Life Sciences Pvt. Ltd. Process for the preparation of alpha form of imatinib mesylate
PL390611A1 (en) 2010-03-04 2011-09-12 Tomasz Koźluk Process for the preparation of polymorphic alpha form and new polymorphic form of imatinib mesylate
CA2792472A1 (en) 2010-03-15 2011-09-22 Natco Pharma Limited Process for the preparation of highly pure crystalline imatinib base
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
US8609842B2 (en) * 2010-04-23 2013-12-17 Fujian South Pharmaceutical Co., Ltd. Method for synthesizing Imatinib
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
JP2013532149A (en) 2010-06-17 2013-08-15 ノバルティス アーゲー Piperidinyl-substituted 1,3-dihydro-benzimidazol-2-ylideneamine derivatives
WO2011157787A1 (en) 2010-06-17 2011-12-22 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
EA024088B1 (en) 2010-06-18 2016-08-31 КРКА, д.д., НОВО МЕСТО Alpha-form of imatinib mesylate, processes for preparation thereof and pharmaceutical composition comprising the same
WO2011160798A1 (en) 2010-06-21 2011-12-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof
BR112012032579B1 (en) 2010-06-24 2021-05-11 Boehringer Ingelheim International Gmbh use of linagliptin and pharmaceutical composition comprising linagliptin and long-acting basal insulin
UA112517C2 (en) 2010-07-06 2016-09-26 Новартіс Аг TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
EP2591004A1 (en) 2010-07-09 2013-05-15 F.Hoffmann-La Roche Ag Anti-neuropilin antibodies and methods of use
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
WO2012019633A1 (en) 2010-08-11 2012-02-16 Synthon B.V. Pharmaceutical granulate comprising imatinib mesylate
TR201007005A2 (en) 2010-08-23 2011-09-21 Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. Imatinib base production method
CN103108871B (en) 2010-09-16 2014-09-10 诺华股份有限公司 17a-hydroxylase/c17,20-lyase inhibitors
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
TR201010618A2 (en) 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut An oral dosage form comprising imatinib and the manufacture of an oral dosage form
AU2011346567A1 (en) 2010-12-21 2013-07-25 Novartis Ag Bi-heteroaryl compounds as Vps34 inhibitors
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
TWI592411B (en) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 Combination of kinase inhibitors and uses thereof
JP5808826B2 (en) 2011-02-23 2015-11-10 インテリカイン, エルエルシー Heterocyclic compounds and uses thereof
CZ305457B6 (en) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidine compounds inhibiting formation of nitrogen monoxide and prostaglandin E2, process for their preparation and use
EP2683722A1 (en) 2011-03-08 2014-01-15 Novartis AG Fluorophenyl bicyclic heteroaryl compounds
PL394169A1 (en) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością The pharmaceutical composition of imatinib mesylate for filling unit dosage forms and the method for its preparation
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2012149413A1 (en) 2011-04-28 2012-11-01 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
EA201391626A1 (en) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-STIMULATED CANCER TYPES
CN102796110B (en) * 2011-05-23 2016-03-30 复旦大学 Aniline pyrimidine compound and its production and use
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
US9750700B2 (en) 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
SG195067A1 (en) 2011-06-27 2013-12-30 Novartis Ag Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
ITMI20111309A1 (en) 2011-07-14 2013-01-15 Italiana Sint Spa PREPARATION PROCEDURE OF IMATINIB MESILATO
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013035102A1 (en) 2011-09-05 2013-03-14 Natco Pharma Limited Processes for the preparation of imatinib base and intermediates thereof
BR112014006223A8 (en) 2011-09-15 2018-01-09 Novartis Ag 6-substituted 3- (quinolin-6-ylthio) - [1,2,4-triazol [4,3-a] pyradines, their uses, pharmaceutical compositions, and combination
CA2853961C (en) 2011-11-01 2016-09-20 Modgene, Llc Compositions and methods for reduction of amyloid-beta load
RU2486180C1 (en) * 2011-11-02 2013-06-27 Общество с ограниченной ответственностью "ТехноХим" (ООО "ТехноХим") Method for preparing 2-arylamino-4-hetarylpyrimidines
EP2785717B1 (en) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidine compounds
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103159739A (en) * 2011-12-09 2013-06-19 天津市国际生物医药联合研究院有限公司 1, 4-disubstituted-1, 2, 3-triazole compounds and preparation method thereof
EP2794594A1 (en) 2011-12-22 2014-10-29 Novartis AG Quinoline derivatives
DK2794600T3 (en) 2011-12-22 2018-03-12 Novartis Ag -2,3-Dihydro-benzo [1,4] oxazine derivatives and related compounds such as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of rheumatoid arthritis
KR20140107575A (en) 2011-12-23 2014-09-04 노파르티스 아게 Compounds for inhibiting the interaction of bcl2 with binding partners
EP2794589A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
JP2015503515A (en) 2011-12-23 2015-02-02 ノバルティス アーゲー COMPOUND AND COMPOSITION FOR INHIBITING BCL2 AND BINDING PARTY INTERACTION
EA201491264A1 (en) 2011-12-23 2014-11-28 Новартис Аг COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL-2 WITH PARTNERS ON BINDING
BR112014015339A2 (en) 2011-12-23 2017-06-13 Novartis Ag compounds for inhibiting bcl2 interaction with binding partners
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
PL226174B1 (en) 2011-12-30 2017-06-30 Inst Farm Combination therapy of non-small-cell lung carcinoma
JO3357B1 (en) 2012-01-26 2019-03-13 Novartis Ag Imidazopyrrolidinone compounds
GB2514285B (en) 2012-02-13 2018-07-18 Grindeks Jsc Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
WO2013136141A1 (en) 2012-03-13 2013-09-19 Fresenius Kabi Oncology Ltd. An improved process for the preparation of alpha form of imatinib mesylate
CN104245701A (en) 2012-04-03 2014-12-24 诺华有限公司 Combination with tyrosine kinase inhibitors and use thereof
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN104379560A (en) 2012-04-24 2015-02-25 中外制药株式会社 Benzamide derivative
BR112014026305A2 (en) 2012-04-24 2017-06-27 Chugai Pharmaceutical Co Ltd quinazolidinedione derivative
JP6469567B2 (en) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Compound for inhibiting cell proliferation of EGFR-activated cancer
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013174768A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
JP6171003B2 (en) 2012-05-24 2017-07-26 ノバルティス アーゲー Pyrrolopyrrolidinone compounds
BR112014031421A2 (en) 2012-06-15 2017-06-27 Brigham & Womens Hospital Inc cancer treatment compositions and methods for producing them
WO2014016848A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
WO2014025395A1 (en) 2012-08-06 2014-02-13 Duke University Compounds and methods for targeting hsp90
WO2014041551A1 (en) 2012-09-14 2014-03-20 Natco Pharma Limited Formulation comprising imatinib as oral solution
CN103664787B (en) 2012-09-17 2015-09-09 南京圣和药业股份有限公司 Alkynes heteroaromatic ring compounds and application thereof
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
WO2014048377A1 (en) 2012-09-28 2014-04-03 杭州本生药业有限公司 Drug composition for treating tumors and application thereof
EP2903979B1 (en) * 2012-10-04 2020-08-19 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
AU2013337247B2 (en) 2012-11-05 2018-08-09 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
TW201422625A (en) 2012-11-26 2014-06-16 Novartis Ag Solid form of dihydro-pyrido-oxazine derivative
CN103848812B (en) * 2012-12-04 2016-08-03 北大方正集团有限公司 The method of refined imatinib
CN103044394A (en) * 2012-12-20 2013-04-17 北京理工大学 Phenyl aminopyrimidine derivant and preparation method and application thereof
EP2749271A1 (en) 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Optimized manufacturing method and pharmaceutical formulation of imatinib
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
KR102509562B1 (en) 2013-02-20 2023-03-14 노파르티스 아게 Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
CN105246482A (en) 2013-03-15 2016-01-13 因特利凯有限责任公司 Combinations of kinase inhibitors and uses thereof
EP3409279A1 (en) 2013-03-15 2018-12-05 Boehringer Ingelheim International GmbH Use of linagliptin in cardio- and renoprotective antidiabetic therapy
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
ES2683361T3 (en) 2013-05-14 2018-09-26 Hetero Research Foundation Imatinib compositions
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (en) 2013-07-24 2015-02-27 Novartis Ag SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
AU2014321419B2 (en) 2013-09-22 2017-06-15 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
WO2015055898A2 (en) 2013-10-17 2015-04-23 Sihto Harri Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient
TW201605805A (en) 2013-10-23 2016-02-16 Chugai Pharmaceutical Co Ltd Quinazolinone and isoquinolinone derivative
TW201605450A (en) 2013-12-03 2016-02-16 諾華公司 Combination of Mdm2 inhibitor and BRAF inhibitor and their use
WO2015148714A1 (en) 2014-03-25 2015-10-01 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP3122730B1 (en) 2014-03-28 2020-03-25 Calitor Sciences, LLC Substituted heteroaryl compounds and methods of use
JP2017513931A (en) 2014-04-03 2017-06-01 インビクタス オンコロジー ピーヴィティー.リミテッド Supramolecular combinatorial treatment
US9630944B2 (en) 2014-04-04 2017-04-25 F.I.S.—Fabbrica Italiana Sintetici S.p.A. Process for preparing Imatinib and salts thereof, free of genotoxic impurity F
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
CN105585556A (en) * 2014-11-13 2016-05-18 连云港杰瑞药业有限公司 Synthetic method of imatinib
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2017129624A1 (en) 2016-01-25 2017-08-03 Krka, D.D., Novo Mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
KR102293847B1 (en) 2016-03-25 2021-08-26 에이비 사이언스 Use of masitinib for the treatment of a subpopulation of patients with amyotrophic lateral sclerosis
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
CN107652269A (en) * 2016-07-26 2018-02-02 江苏豪森药业集团有限公司 Methanesulfonic acid fluorine imatinib purification of intermediate method
WO2018039205A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
WO2018039203A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating multiple myeloma
CN107805240A (en) * 2016-09-08 2018-03-16 中国科学院合肥物质科学研究院 A kind of new PDGFR kinase inhibitors and application thereof
MX389789B (en) 2016-09-27 2025-03-20 Cero Therapeutics Inc CHIMERICAL ENVELOPEMENT RECEPTOR MOLECULES.
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
EP3333162A1 (en) 2016-12-12 2018-06-13 Silesian Catalysts sp. z o.o. Metod for preparing n-(2-methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine
CN107089969B (en) * 2017-04-26 2020-04-24 黑龙江鑫创生物科技开发有限公司 Method for synthesizing imatinib intermediate
WO2019067328A1 (en) 2017-09-26 2019-04-04 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
CA3079422A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
WO2019083960A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. Peptide vaccines and hdac inhibitors for treating multiple myeloma
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
EP3730483B1 (en) 2017-12-21 2023-08-30 Hefei Institutes of Physical Science, Chinese Academy of Sciences Class of pyrimidine derivative kinase inhibitors
JP7450541B2 (en) 2018-01-20 2024-03-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Substituted aminopyrimidine compounds and methods of use
RU2020135107A (en) 2018-03-28 2022-04-29 Серо Терапьютикс, Инк. CELLULAR IMMUNOTHERAPEUTIC COMPOSITIONS AND THEIR APPLICATIONS
US12291557B2 (en) 2018-03-28 2025-05-06 Cero Therapeutics Holdings, Inc. Chimeric TIM4 receptors and uses thereof
US20210024607A1 (en) 2018-03-28 2021-01-28 Cero Therapeutics, Inc. Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
BR112020026164A2 (en) 2018-07-17 2021-03-23 Boehringer Ingelheim International Gmbh cardioprotective and nephroprotective antidiabetic therapy
KR20210032468A (en) 2018-07-17 2021-03-24 베링거 인겔하임 인터내셔날 게엠베하 Heart-safe antidiabetic therapy
WO2020023628A1 (en) 2018-07-24 2020-01-30 Hygia Pharmaceuticals, Llc Compounds, derivatives, and analogs for cancer
WO2021009686A1 (en) 2019-07-15 2021-01-21 Intas Pharmaceuticals Ltd. Pharmaceutical composition of imatinib
EP4038097A1 (en) 2019-10-03 2022-08-10 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides
WO2021233534A1 (en) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021185844A1 (en) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
US12359208B2 (en) 2020-04-15 2025-07-15 California Institute Of Technology Thermal control of T-cell immunotherapy through molecular and physical actuation
WO2021228983A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
WO2022029220A1 (en) 2020-08-05 2022-02-10 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
WO2022036265A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Chimeric tim receptors and uses thereof
WO2022036285A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
WO2022036287A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Anti-cd72 chimeric receptors and uses thereof
WO2022047259A1 (en) 2020-08-28 2022-03-03 California Institute Of Technology Synthetic mammalian signaling circuits for robust cell population control
TW202237638A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
WO2022183072A1 (en) 2021-02-26 2022-09-01 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
JP2024529474A (en) 2021-07-28 2024-08-06 セロ・セラピューティクス・インコーポレイテッド Chimeric Tim4 receptor and uses thereof
IL318710A (en) 2022-08-02 2025-03-01 Univ Hokkaido Nat Univ Corp Methods of improving cellular therapy with organelle complexes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1570555A (en) * 1977-04-05 1980-07-02 Taiho Pharmaceutical Co Ltd Anti-cancer composition
SG47583A1 (en) * 1986-01-13 1998-04-17 American Cyanamid Co 4,5,6-Substituted-n- (substituted-phenyl) -2- pyrimidinamines

Also Published As

Publication number Publication date
DE10299016I2 (en) 2006-08-24
JP2706682B2 (en) 1998-01-28
PT564409E (en) 2000-06-30
CN1077713A (en) 1993-10-27
SK280620B6 (en) 2000-05-16
CZ283944B6 (en) 1998-07-15
AU666709B2 (en) 1996-02-22
NZ247299A (en) 1995-07-26
AU3569493A (en) 1993-10-07
JPH0687834A (en) 1994-03-29
CY2003003I1 (en) 2010-07-28
MX9301929A (en) 1994-07-29
HU226488B1 (en) 2009-03-02
HU227080B1 (en) 2010-06-28
FI109534B (en) 2002-08-30
NO931283L (en) 1993-10-04
NO931283D0 (en) 1993-04-02
DE10299016I1 (en) 2002-08-29
CA2093203A1 (en) 1993-10-04
HUT64050A (en) 1993-11-29
ZA932397B (en) 1993-10-04
NO2002001I2 (en) 2007-01-29
HU9300982D0 (en) 1993-06-28
FI931458A7 (en) 1993-10-04
EP0564409B1 (en) 2000-01-19
IL105264A0 (en) 1993-08-18
NL300086I1 (en) 2002-05-01
KR100261366B1 (en) 2002-07-18
SA93140441B1 (en) 2005-12-14
DK0564409T3 (en) 2000-06-19
GR3032927T3 (en) 2000-07-31
ES2142857T3 (en) 2000-05-01
ATE188964T1 (en) 2000-02-15
IL105264A (en) 1999-04-11
CY2229B1 (en) 2003-04-18
SK28093A3 (en) 1994-04-06
EP0564409A1 (en) 1993-10-06
BR1100739A (en) 2000-06-06
RU2125992C1 (en) 1999-02-10
NL300086I2 (en) 2002-06-03
KR930021624A (en) 1993-11-22
CN1043531C (en) 1999-06-02
SG43859A1 (en) 1997-11-14
CZ56093A3 (en) 1994-02-16
DE59309931D1 (en) 2000-02-24
LU90908I2 (en) 2003-04-30
TW225528B (en) 1994-06-21
NO302473B1 (en) 1998-03-09
CA2093203C (en) 2002-11-26

Similar Documents

Publication Publication Date Title
FI931458A0 (en) PYRIMIDINDERIVAT OCH FOERFARANDE FOER DERAS FRAMSTAELLNING
MY107756A (en) Piperazine derivatives.
RU93005357A (en) Pyrimidine derivatives and method of their manufacture
DE69902634D1 (en) SUBSTITUTED AMINOPHENYLISOXAZOLINE DERIVATIVES USED AS ANTIMICROBIAL AGENTS
ATE144772T1 (en) PIPERAZINE DERIVATIVES
DE69230916D1 (en) Piperazine derivatives as collagenase inhibitors
NZ218243A (en) B-carboline derivatives and pharmaceutical compositions
MY129935A (en) Dihydropyridine derivatives useful in antitumor therapy
DE69321609D1 (en) PIPERAZINE DERIVATIVES
BG101601A (en) PHARMACEUTICAL PIPERAZINE DERIVATIVES
DE69413213D1 (en) PIPERAZINE DERIVATIVES AS 5-HT1A LIGANDS
DE69431471D1 (en) AMIDE DERIVATIVES AS 5-HT1A LIGANDS
ATE504572T1 (en) INTEGRAS INHIBITORS CONTAINING DERIVATIVES OF AROMATIC HETEROCYCLES
GB1185524A (en) Quinazolinone Derivatives
TW257758B (en) Piperazine derivatives (1)

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20030003

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 231

MA Patent expired
PC Transfer of assignment of patent

Owner name: NOVARTIS PHARMA AG

SPCP Extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: 231

Extension date: 20161221